CORE Group, the drug delivery company based in Kilmarnock, announced yesterday that one of its re-formulated feminine healthcare products had successfully completed a clinical study and would enter pivotal trials in the UK and US by the middle of this year.
However, it was also revealed that development of another female healthcare product for the treatment of thrush had been discontinued. This product uses the same delivery system as the successful treatment for bacterial vaginosis.
The system developed by Core, known as Hycore-VTM, is aimed at a controlled and cleaner delivery of existing drugs used in feminine healthcare. In the case of the product for thrush, it was determined that Miconazole was not the appropriate drug for use with the Hycore system.
Core chief executive Jim Pickard said there were a number of other drugs that might replace Miconazole in the Hycore treatment for thrush, although a successor has not yet been identified. He added that the company was talking to a few potential partners about the female healthcare range, and the preferred partner was ''aware of the situation, but not concerned''.
In fact, he hopes the successful clinical study for the bacterial vaginosis product will help accelerate negotiations.
Core is in discussions with the US Food and Drug Administration (FDA) about the structure for the next set of clinical trials. Recruitment of patients begins shortly, with the study expected to begin in the middle of the year.
Core's other lead product, the Moraxen morphine pessary to ease pain in terminal cancer patients, is due to be launched later this year. This product will be marketed in conjunction with German group Schwarz Pharma.
The Ayrshire-based company's share price took a serious knock last year when the development timetable for Moraxen and the Hycore treatments were set back.
The company's shares, which floated at 250p in April 1997, have since been on a downward slide to yesterday's closing price of 38.5p.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article